Polynucleotides Injectable Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Eyes, Lips, Forehead, Jawline & Cheekbones, Others), By End Use (Med Spas, Aesthetic & Cosmetic Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 136.12 MIllion
CAGR (2026-2031)	9.71%
Fastest Growing Segment	Eyes
Largest Market	North America
Market Size (2031)	USD 237.36 MIllion

Market Overview

The Global Polynucleotides Injectable Market will grow from USD 136.12 MIllion in 2025 to USD 237.36 MIllion by 2031 at a 9.71% CAGR. The Global Polynucleotides Injectable Market consists of biostimulatory products containing ultra-pure DNA fractions, typically derived from salmon or trout, which are injected to activate fibroblasts and promote physiological tissue regeneration, hydration, and collagen synthesis without adding artificial volume. The primary driver supporting market growth is the fundamental shift in consumer preference toward regenerative aesthetics and natural-looking results, as patients increasingly prioritize skin quality improvement and cellular repair over traditional volume-enhancing fillers.

However, a significant challenge that could impede market expansion is the fragmented regulatory landscape, where inconsistent product classifications between medical devices and pharmaceuticals across different jurisdictions create barriers to global standardization and approval. Highlighting the rapid adoption of these therapies among professionals, according to the Korean Aesthetic Surgery and Laser Society, in 2024, 75.7% of surveyed cosmetic physicians reported utilizing polynucleotide injections to treat enlarged facial pores caused by excessive sebum production.

Key Market Drivers

Surging Global Demand for Minimally Invasive Anti-Aging Procedures drives market expansion. Patients increasingly prioritize treatments offering structural improvement and natural results with minimal downtime, diverging from the immediate volume enhancement of traditional fillers. This shift is evidenced by the substantial volume of non-invasive treatments; according to the International Society of Aesthetic Plastic Surgery, June 2024, in the 'Global Survey on Aesthetic/Cosmetic Procedures', 19.1 million non-surgical procedures were performed worldwide in 2023, reflecting a sustained appetite for needle-based therapies. Polynucleotides capitalize on this trend by initiating physiological repair processes that improve skin elasticity and hydration from within, meeting the consumer desire for regenerative solutions.

Growing Application Scope in Hair Restoration and Alopecia Treatment simultaneously expands the addressable market. These injectables are gaining traction for androgenetic alopecia by stimulating microcirculation and follicle cell proliferation. Clinical evidence supports this efficacy; according to a study published in the Archives of Dermatological Research, 2024, 77.8% of patients treated with polynucleotide injections reported slight to moderate hair regrowth improvement after 18 weeks. This therapeutic versatility has fostered high adoption rates among practitioners; according to a survey published in the Journal of Cosmetic Dermatology, April 2024, 88% of board-certified dermatologists in South Korea reported incorporating polynucleotide injections into their practice, underscoring the product class's expanding utility across diverse aesthetic indications.

Download Free Sample Report

Key Market Challenges

The challenging factor identifying the fragmented regulatory landscape acts as a substantial brake on the Global Polynucleotides Injectable Market by creating a complex and costly barrier to entry for manufacturers. Inconsistent product classifications, where polynucleotides are categorized as medical devices in some jurisdictions and pharmaceuticals in others, force companies to navigate divergent approval pathways. This lack of harmonization necessitates separate, capital-intensive clinical trials and compliance strategies for each region, significantly delaying product launches and restricting the global availability of these injectables.

This regulatory bottleneck directly stifles market expansion by preventing supply from meeting the surging professional interest in regenerative aesthetics. According to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), in 2024, 57% of facial plastic surgeons identified regenerative medicine as a major area of innovation. Despite this clear indicator of market readiness and high practitioner demand, the regulatory friction limits the number of approved polynucleotide products accessible to these professionals. Consequently, the market's potential is artificially capped, as the slow pace of regulatory clearance in key economies prevents these therapies from achieving the widespread adoption rates seen in more standardized aesthetic categories.

Key Market Trends

The Emergence of Pre-juvenation Strategies among Younger Demographics is rapidly altering patient acquisition patterns within the Global Polynucleotides Injectable Market. Younger consumers, particularly Millennials and Gen Z, are increasingly utilizing these biostimulators not for correction, but as a preventative measure to maintain skin quality and delay aging signs. This demographic is drawn to the ability of polynucleotides to enhance hydration and texture without the structural changes associated with traditional fillers, aligning with the "glass skin" aesthetic trend. This surge in consumer interest is quantifiable; according to DermaFocus, December 2024, in the article 'Why Polynucleotides HPT is THE Technology to Invest In', market data highlighted a dramatic 2,446% increase in internet searches for polynucleotides over the preceding months, driven largely by patients seeking these preventative, celebrity-endorsed skin regimens.

Increasing Utilization in Male Grooming and Aesthetic Regimens represents a second pivotal trend widening the therapy's application scope. Male patients are gravitating toward polynucleotide injections because they offer skin revitalization and improved elasticity without adding artificial volume, which can feminize facial features. This aligns with the male preference for undetectable treatments that maintain masculine structural definition while addressing specific concerns like acne scarring or coarse skin texture. Professional clinical data corroborates this demographic shift; according to the British College of Aesthetic Medicine, September 2024, in the 'BCAM 2024 Annual Clinical Review', 16% of all patients treated by member physicians identified as male, indicating a sustained integration of these bio-regenerative protocols into men's aesthetic maintenance routines.

Segmental Insights

Based on recent industry analysis, the Eyes segment is currently positioned as the fastest-growing application area within the Global Polynucleotides Injectable Market. This expansion is primarily driven by the unique efficacy of polynucleotides in treating the delicate periorbital region, where traditional hyaluronic acid fillers pose risks such as fluid retention or the Tyndall effect. Polynucleotides function by stimulating fibroblasts to regenerate tissue and improve skin density, offering a safer biological solution for dark circles and fine lines. Consequently, practitioners are increasingly adopting these injectables to provide natural restoration for thin under-eye skin.

Regional Insights

North America maintains a leading position in the Global Polynucleotides Injectable Market, supported by an advanced healthcare infrastructure and high disposable income levels. The region’s dominance is fueled by a surging consumer demand for minimally invasive anti-aging treatments and skin rejuvenation therapies. Additionally, the United States houses prominent biotechnology companies that prioritize research and development in regenerative medicine, ensuring a steady pipeline of product innovations. The extensive network of specialized dermatology clinics and medical spas further accelerates market adoption, making these aesthetic solutions readily accessible to a broad patient base.

Recent Developments

• In March 2025, Croma-Pharma announced the rebranding of its injectable polynucleotide range from PhilArt to PolyPhil. The company stated that the new name was selected to better reflect the product's advanced technology and to support its expansion into international markets. This rebranding initiative aimed to enhance global brand awareness while maintaining the same product quality and efficacy, which is based on high purification technology. The Head of Marketing for the UK, Ireland, and Netherlands noted that the name change would help encompass the product's functions more clearly as demand for polynucleotide treatments continued to grow globally.
• In January 2025, DermaFocus released the results of a clinical study demonstrating the effectiveness of Polynucleotides HPT® for improving skin quality specifically in Asian patients. The research, which was coordinated by medical directors in Malaysia, assessed the impact of the injectable treatment on skin tone, surface evenness, firmness, and glow over a six-month period. The findings indicated significant improvements across all evaluated categories, with high patient satisfaction rates and no severe adverse effects reported. This study provided crucial data supporting the use of polynucleotides for addressing photoaging and skin barrier function in Asian skin types.
• In July 2024, PharmaResearch hosted a launch symposium in Singapore to officially introduce Rejuran HB Plus, a new skin booster formulation combining polynucleotides and hyaluronic acid. The event gathered aesthetic experts and medical professionals to discuss the product's clinical efficacy and the company's proprietary DNA Optimizing Technology (DOT™). Rejuran HB Plus was presented as an advanced solution that includes lidocaine to minimize patient discomfort during treatment. This launch marked a strategic move by the company to solidify its presence in the Asian medical aesthetics market and promote its polynucleotide-based innovations.
• In March 2024, Croma-Pharma announced a strategic partnership with Megalabs to expand the distribution of its aesthetic portfolio across Latin America. The agreement involved the divestiture of Croma’s affiliate in Brazil and granted Megalabs distribution rights for a range of products, including hyaluronic acid fillers and polynucleotide injectables. This collaboration aimed to leverage Megalabs' established market position in dermatology to increase the accessibility of Croma’s minimally invasive aesthetic solutions in the region. The CEO of Croma-Pharma highlighted that the comprehensive portfolio, supported by clinical studies, would significantly strengthen their footprint in the Latin American market.

Key Market Players

• PharmaResearch
• Bioplus Co., Ltd.
• AMEELA
• Mastelli Srl
• MD Skin Solutions
• Fox Pharma Ltd
• BRPHARM Co., Ltd.
• DermaFocus Ltd
• ADM Skin Clinic
• The Doctor & Company

By Application	By End Use	By Region
Eyes Lips Forehead Jawline & Cheekbones Others	Med Spas Aesthetic & Cosmetic Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Polynucleotides Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Polynucleotides Injectable Market, By Application:

• Eyes
• Lips
• Forehead
• Jawline & Cheekbones
• Others

• Polynucleotides Injectable Market, By End Use:

• Med Spas
• Aesthetic & Cosmetic Centers
• Others

• Polynucleotides Injectable Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE